Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
Clearmind Medicine Inc. filed this Form 6-K on December 10, 2025, to announce a corporate action regarding its capital structure. The filing pertains to the month of December 2025 and details the implementation of a reverse share split.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the mechanics of a reverse share split.
Material Changes
- Reverse Share Split: The Company will effect a 1-for-40 reverse share split of its common shares.
- Share Count Adjustment: Issued and outstanding common shares will be adjusted from 59,991,852 to 1,499,796 (subject to fractional share treatment).
- Fractional Shares: No fractional shares will be issued; all fractional interests will be rounded up to the nearest whole share.
- Derivatives Adjustment: A proportionate adjustment will be made to the per-share exercise price and the number of shares issuable for all outstanding warrants and options.
- Trading Resumption: Trading on the Nasdaq Capital Market under the new structure will commence on Monday, December 15, 2025.
- Identification: The new CUSIP number for the common shares will be 185053501.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release containing "Forward-Looking Statements," but the text of this Form 6-K does not provide specific details on future guidance, management commentary on operations, or specific risk factors beyond the structural changes described. The filing notes that the authorized share capital will remain unchanged.
Investor Verification Checklist
- Verify the effective date of the reverse split (December 15, 2025) and the new CUSIP number (185053501) with your brokerage.
- Confirm the treatment of fractional shares in your specific account, as the Company rounds up to the nearest whole share.
- Review the adjusted exercise prices and share counts for any outstanding options or warrants held.
- Check the Company's Form 20-F for the most recent audited financial statements, as this 6-K contains no financial data.